Business● LowOct 29 · Oct 29, 2026, 6:59 AM
Vanda targets full-year 2026 total revenues greater than $240M as BYSANTI launch nears Q4
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Vanda Pharmaceuticals is targeting total revenues exceeding $240 million for the full year 2026. This projection is made in anticipation of the BYSANTI product launch, which is nearing in the fourth quarter.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business19m agoNvidia scandal weakens thesis on chip sales to ChinaFolha de S.Paulo · BrazilBusiness25m agoGiants’ daunting schedule will reveal if they’re legitimate playoff contendersNY Post · United StatesBusiness33m agoBessent upset Lutnick didn't ban Nvidia chip exports to China-linked firmCBS NewsBusiness48m ago‘It all fell apart’: Upper north shore Hamptons-style home passes in at auctionSydney Morning Herald · Australia